IMAB – I-Mab ADR
I-MABIMAB
$0.8452Name : I-MAB
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $68,884,736.00
EPSttm : -0.62
I-MAB
$0.8452
0.62%$0.0052Float Short %
0.42
Margin Of Safety %
Put/Call OI Ratio
0.15
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
-0.01
Price
0.85
Target Price
5.67
Analyst Recom
1
Performance Q
-23.16
Relative Volume
0.13
Beta
1.09
Ticker: IMAB
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-21 | IMAB | 0.8599 | 0.10 | 0.00 | 1463 |
| 2025-03-24 | IMAB | 0.8592 | 0.17 | 0.00 | 936 |
| 2025-03-25 | IMAB | 0.8703 | 0.17 | 0.00 | 936 |
| 2025-03-26 | IMAB | 0.8372 | 0.17 | 0.00 | 936 |
| 2025-03-27 | IMAB | 0.8413 | 0.19 | 0.00 | 857 |
| 2025-03-28 | IMAB | 0.8101 | 0.18 | 0.00 | 867 |
| 2025-03-31 | IMAB | 0.7997 | 0.18 | 0.00 | 867 |
| 2025-04-01 | IMAB | 0.7782 | 0.18 | 0.00 | 867 |
| 2025-04-02 | IMAB | 0.783 | 0.18 | 0.00 | 884 |
| 2025-04-03 | IMAB | 0.7408 | 0.18 | 0.00 | 884 |
| 2025-04-04 | IMAB | 0.6751 | 0.16 | 0.00 | 993 |
| 2025-04-07 | IMAB | 0.6203 | 0.15 | 0.00 | 1038 |
| 2025-04-08 | IMAB | 0.6752 | 0.15 | 0.00 | 1038 |
| 2025-04-09 | IMAB | 0.6881 | 0.15 | 0.00 | 1038 |
| 2025-04-10 | IMAB | 0.6735 | 0.15 | 0.00 | 1039 |
| 2025-04-11 | IMAB | 0.6692 | 0.15 | 0.00 | 1039 |
| 2025-04-14 | IMAB | 0.9563 | 0.15 | 0.00 | 1040 |
| 2025-04-15 | IMAB | 0.9198 | 0.15 | 0.00 | 1040 |
| 2025-04-16 | IMAB | 0.8404 | 0.15 | 0.00 | 1040 |
| 2025-04-17 | IMAB | 0.85 | 0.15 | 0.00 | 1040 |
| 2025-04-18 | IMAB | 0.8452 | 0.15 | 0.00 | 1040 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-21 | IMAB | 0.86 | - | - | -0.13 |
| 2025-03-24 | IMAB | 0.87 | - | - | -0.13 |
| 2025-03-25 | IMAB | 0.87 | - | - | -0.13 |
| 2025-03-26 | IMAB | 0.84 | - | - | -0.13 |
| 2025-03-27 | IMAB | 0.84 | - | - | -0.13 |
| 2025-03-28 | IMAB | 0.84 | - | - | -0.13 |
| 2025-03-31 | IMAB | 0.82 | - | - | -0.13 |
| 2025-04-01 | IMAB | 0.79 | - | - | -0.13 |
| 2025-04-02 | IMAB | 0.78 | - | - | -0.13 |
| 2025-04-03 | IMAB | 0.73 | - | - | -0.13 |
| 2025-04-04 | IMAB | 0.67 | - | - | -0.13 |
| 2025-04-07 | IMAB | 0.62 | - | - | -0.29 |
| 2025-04-08 | IMAB | 0.69 | - | - | -0.29 |
| 2025-04-09 | IMAB | 0.69 | - | - | -0.29 |
| 2025-04-10 | IMAB | 0.67 | - | - | -0.29 |
| 2025-04-11 | IMAB | 0.66 | - | - | -0.29 |
| 2025-04-14 | IMAB | 0.96 | - | - | -0.28 |
| 2025-04-15 | IMAB | 0.91 | - | - | -0.28 |
| 2025-04-16 | IMAB | 0.85 | - | - | -0.28 |
| 2025-04-17 | IMAB | 0.85 | - | - | -0.28 |
| 2025-04-18 | IMAB | 0.85 | - | - | -0.28 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-21 | IMAB | 0.00 | -27.10 | 1.15 |
| 2025-03-24 | IMAB | 0.00 | -27.29 | 1.15 |
| 2025-03-25 | IMAB | 0.00 | -27.29 | 1.15 |
| 2025-03-26 | IMAB | 0.00 | -27.29 | 1.22 |
| 2025-03-27 | IMAB | 0.00 | -27.29 | 1.22 |
| 2025-03-28 | IMAB | 0.00 | -27.29 | 1.22 |
| 2025-03-31 | IMAB | 0.00 | -27.38 | 1.22 |
| 2025-04-01 | IMAB | 0.00 | -27.38 | 1.22 |
| 2025-04-02 | IMAB | 0.00 | -27.38 | 1.22 |
| 2025-04-03 | IMAB | 0.00 | -27.38 | 1.22 |
| 2025-04-04 | IMAB | 0.00 | -27.38 | 1.22 |
| 2025-04-07 | IMAB | 0.00 | -26.94 | 0 |
| 2025-04-08 | IMAB | 0.00 | -26.94 | 1.20 |
| 2025-04-09 | IMAB | 0.00 | -26.94 | 1.20 |
| 2025-04-10 | IMAB | 0.00 | -26.94 | 0.42 |
| 2025-04-11 | IMAB | 0.00 | -26.94 | 0.42 |
| 2025-04-14 | IMAB | 0.00 | -27.21 | 0.42 |
| 2025-04-15 | IMAB | 0.00 | -27.21 | 0.42 |
| 2025-04-16 | IMAB | 0.00 | -27.21 | 0.42 |
| 2025-04-17 | IMAB | 0.00 | -27.21 | 0.42 |
| 2025-04-18 | IMAB | 0.00 | -27.21 | 0.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
Institutional Transactions
-27.21
Beta
1.09
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
13
Growth Score
20
Sentiment Score
85
Actual DrawDown %
99
Max Drawdown 5-Year %
-99.3
Target Price
5.67
P/E
Forward P/E
PEG
P/S
P/B
0.33
P/Free Cash Flow
EPS
-0.71
Average EPS Est. Cur. Y
-0.28
EPS Next Y. (Est.)
-0.29
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.13
Return on Equity vs Sector %
-31
Return on Equity vs Industry %
-17.6
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.18
EBIT Estimation
I-MABSector: Healthcare
Industry: Biotechnology
Employees: 32
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has collaboration with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
stock quote shares IMAB – I-Mab ADR Stock Price stock today
news today IMAB – I-Mab ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMAB – I-Mab ADR yahoo finance google finance
stock history IMAB – I-Mab ADR invest stock market
stock prices IMAB premarket after hours
ticker IMAB fair value insiders trading